NeuroOne Medical Technologies (NMTC)
Market Price (4/19/2026): $4.87 | Market Cap: $40.9 MilSector: Health Care | Industry: Life Sciences Tools & Services
NeuroOne Medical Technologies (NMTC)
Market Price (4/19/2026): $4.87Market Cap: $40.9 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 52% Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -81% Megatrend and thematic driversMegatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Personalized Diagnostics, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -128%, 3Y Excs Rtn is -167% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -7.6 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -88% Weak revenue growthRev Chg QQuarterly Revenue Change % is -12% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 15% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -71%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -72% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -21% High stock price volatilityVol 12M is 112% Key risksNMTC key risks include [1] significant net losses and a reliance on securing additional capital to fund operations, Show more. |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 52% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -81% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Personalized Diagnostics, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -128%, 3Y Excs Rtn is -167% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -7.6 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -88% |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -12% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 15% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -71%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -72% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -21% |
| High stock price volatilityVol 12M is 112% |
| Key risksNMTC key risks include [1] significant net losses and a reliance on securing additional capital to fund operations, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Significant Decline in Licensing Revenue and Year-over-Year Product Revenue.
NeuroOne Medical Technologies reported no license revenue in the first quarter of fiscal year 2026, compared to $3 million in the same quarter of the prior fiscal year from an expanded distribution agreement. Additionally, product revenue decreased to $2.9 million in Q1 Fiscal 2026, down from $3.3 million in Q1 Fiscal 2025, largely attributed to the absence of an initial stocking order from Zimmer in the previous year.
2. Deteriorating Cash Position.
The company experienced a substantial decrease in its cash and cash equivalents, which fell to $3.6 million as of December 31, 2025, from $6.6 million as of September 30, 2025. This indicates a significant cash burn and raises concerns about the company's liquidity.
Show more
Stock Movement Drivers
Fundamental Drivers
The -82.3% change in NMTC stock from 12/31/2025 to 4/18/2026 was primarily driven by a -81.4% change in the company's P/S Multiple.| (LTM values as of) | 12312025 | 4182026 | Change |
|---|---|---|---|
| Stock Price ($) | 27.29 | 4.84 | -82.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 9 | 9 | -4.2% |
| P/S Multiple | 25.0 | 4.7 | -81.4% |
| Shares Outstanding (Mil) | 8 | 8 | -0.5% |
| Cumulative Contribution | -82.3% |
Market Drivers
12/31/2025 to 4/18/2026| Return | Correlation | |
|---|---|---|
| NMTC | -82.3% | |
| Market (SPY) | -5.4% | 1.9% |
| Sector (XLV) | -3.9% | 3.9% |
Fundamental Drivers
The -84.9% change in NMTC stock from 9/30/2025 to 4/18/2026 was primarily driven by a -88.1% change in the company's P/S Multiple.| (LTM values as of) | 9302025 | 4182026 | Change |
|---|---|---|---|
| Stock Price ($) | 31.99 | 4.84 | -84.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 7 | 9 | 31.5% |
| P/S Multiple | 39.1 | 4.7 | -88.1% |
| Shares Outstanding (Mil) | 8 | 8 | -3.4% |
| Cumulative Contribution | -84.9% |
Market Drivers
9/30/2025 to 4/18/2026| Return | Correlation | |
|---|---|---|
| NMTC | -84.9% | |
| Market (SPY) | -2.9% | 15.8% |
| Sector (XLV) | 7.4% | 8.7% |
Fundamental Drivers
The -84.2% change in NMTC stock from 3/31/2025 to 4/18/2026 was primarily driven by a -83.0% change in the company's P/S Multiple.| (LTM values as of) | 3312025 | 4182026 | Change |
|---|---|---|---|
| Stock Price ($) | 30.61 | 4.84 | -84.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 6 | 9 | 51.6% |
| P/S Multiple | 27.4 | 4.7 | -83.0% |
| Shares Outstanding (Mil) | 5 | 8 | -38.7% |
| Cumulative Contribution | -84.2% |
Market Drivers
3/31/2025 to 4/18/2026| Return | Correlation | |
|---|---|---|
| NMTC | -84.2% | |
| Market (SPY) | 16.3% | 23.9% |
| Sector (XLV) | 3.3% | 18.4% |
Fundamental Drivers
The -91.6% change in NMTC stock from 3/31/2023 to 4/18/2026 was primarily driven by a -99.3% change in the company's P/S Multiple.| (LTM values as of) | 3312023 | 4182026 | Change |
|---|---|---|---|
| Stock Price ($) | 57.96 | 4.84 | -91.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 9 | 3358.8% |
| P/S Multiple | 622.2 | 4.7 | -99.3% |
| Shares Outstanding (Mil) | 3 | 8 | -67.8% |
| Cumulative Contribution | -91.6% |
Market Drivers
3/31/2023 to 4/18/2026| Return | Correlation | |
|---|---|---|
| NMTC | -91.6% | |
| Market (SPY) | 63.3% | 13.8% |
| Sector (XLV) | 20.3% | 10.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| NMTC Return | 1% | -38% | 32% | -48% | -8% | -83% | -93% |
| Peers Return | 12% | -7% | 10% | 15% | 18% | -11% | 39% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 3% | 87% |
Monthly Win Rates [3] | |||||||
| NMTC Win Rate | 17% | 50% | 50% | 25% | 42% | 50% | |
| Peers Win Rate | 53% | 50% | 53% | 58% | 62% | 40% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| NMTC Max Drawdown | -2% | -73% | -29% | -63% | -48% | -84% | |
| Peers Max Drawdown | -6% | -22% | -9% | -4% | -2% | -15% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: MDT, BSX, ABT, SYK, JNJ.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/17/2026 (YTD)
How Low Can It Go
| Event | NMTC | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -92.9% | -25.4% |
| % Gain to Breakeven | 1313.2% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -28.6% | -33.9% |
| % Gain to Breakeven | 40.0% | 51.3% |
| Time to Breakeven | 429 days | 148 days |
| 2018 Correction | ||
| % Loss | -57.1% | -19.8% |
| % Gain to Breakeven | 133.3% | 24.7% |
| Time to Breakeven | 596 days | 120 days |
Compare to MDT, BSX, ABT, SYK, JNJ
In The Past
NeuroOne Medical Technologies's stock fell -92.9% during the 2022 Inflation Shock from a high on 6/3/2021. A -92.9% loss requires a 1313.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About NeuroOne Medical Technologies (NMTC)
AI Analysis | Feedback
Here are 1-2 brief analogies for NeuroOne Medical Technologies (NMTC):
A Medtronic focused on next-generation neurological electrodes for the brain and spine.
Like a specialized Abbott or Boston Scientific, creating 'see-and-treat' electrode solutions for neurological conditions.
AI Analysis | Feedback
- Thin Film Electrode Technology: This core technology forms the basis for their advanced medical devices designed for various neurological applications.
- cEEG Recording Solutions: Devices leveraging their thin film electrodes for continuous electroencephalogram recording of brain activity.
- sEEG Recording Solutions: Devices employing their thin film electrodes for stereoelectroencephalography recording, enabling invasive brain activity monitoring.
- Spinal Cord Stimulation Solutions: Therapeutic devices developed for the stimulation of the spinal cord to manage various neurological conditions.
- Brain Stimulation Solutions: Therapeutic devices designed for the stimulation of specific brain regions to address neurological disorders.
- Ablation Solutions: Integrated systems, including specialized electrodes, for ablating (destroying) targeted brain tissue.
- Radio Frequency Ablation Generator: A device under development, in partnership, to power their ablation electrodes for precise tissue destruction.
AI Analysis | Feedback
Based on the provided description, NeuroOne Medical Technologies (NMTC) sells its medical devices and technology primarily to other companies or institutions rather than directly to individuals. The company's products are used in medical procedures for neurological disorders, indicating their customers are healthcare providers.
The major categories of customers for NeuroOne Medical Technologies are:
- Hospitals (particularly departments specializing in neurology, neurosurgery, and epilepsy monitoring units)
- Surgical Centers
- Specialized Neurology Clinics
The provided background information does not name specific major customer companies or institutions. Therefore, specific names and symbols of customer companies cannot be listed.
AI Analysis | Feedback
- Integer Holdings Corporation (ITGR)
- ArcLight Manufacturing, Inc.
- Plexus Corp. (PLXS)
- RBC Medical Innovations
AI Analysis | Feedback
David Rosa, President & Chief Executive OfficerMr. Rosa has served as NeuroOne's Chief Executive Officer since July 2017. He holds an MBA from Duquesne University and a B.S. in Commerce & Engineering from Drexel University. Mr. Rosa previously led medtech businesses including Sunshine Heart (now Nuwellis) from 2014 to 2015 and Milksmart from 2008 to 2009. He also served as Vice President Global Marketing at St. Jude Medical from 2004 to 2008. His three-decade career in the medical device industry includes senior roles at C.R. Bard Inc. and Boston Scientific Inc. Mr. Rosa is an inventor on multiple medical device patents, serves on seven corporate boards, and has raised $200 million in the capital markets.
Ronald McClurg, Chief Financial Officer and Principal Accounting OfficerMr. McClurg was appointed Chief Financial Officer of NeuroOne in January 2021. He brings over 30 years of financial leadership experience with both public and privately held companies. His previous CFO roles for public companies include Orthomet, Inc., Video Sentry Corporation, and Insignia Systems, Inc. Mr. McClurg also served as CFO of Incisive Surgical, Inc., a privately held medical device company, from October 2003 to June 2019, where he managed capital raising, financial reporting, budgeting, and risk management. He began his career in public accounting with Ernst and Young, earning his CPA certificate. Mr. McClurg holds a Bachelor of Business Administration degree in accounting from the University of Wisconsin–Eau Claire and serves on the boards of Biotricity and Healthcare Triangle as Audit Chair.
Christopher R. Volker, Chief Operating OfficerMr. Volker serves as the Chief Operating Officer of NeuroOne Medical Technologies.
Steve Mertens, Chief Technology OfficerMr. Mertens holds the position of Chief Technology Officer at NeuroOne Medical Technologies.
Mark Christianson, Co-Founder, Business Development Director, Medical Sales LiaisonMr. Christianson is a co-founder of NeuroOne Medical Technologies Corporation, which was established on August 20, 2009. He serves as the Business Development Director and Medical Sales Liaison for the company. He is also listed as the VP of Business Development & Marketing.
AI Analysis | Feedback
The key risks to NeuroOne Medical Technologies' business are:-
Need for new capital and cash burn: NeuroOne Medical Technologies is currently burning cash, necessitating a constant need for new capital to fund its operations and development. The company's financial statements show it is still operating at a net loss, and its ability to convert technological promise into commercial scale before exhausting its cash reserves is a critical concern.
-
Competition from established players: The company faces significant threats from the sheer scale and resources of established competitors in the medical device industry, such as Medtronic, which can make market penetration and sustained growth challenging for a micro-cap medical device company.
-
Execution risk and commercialization challenges: NeuroOne Medical Technologies faces inherent execution risks related to the timely FDA clearance of its products and the successful commercialization of its thin-film electrode technology. Delays in regulatory approvals or slower-than-anticipated market adoption can significantly impact the company's financial runway and its ability to meet projected revenue targets.
AI Analysis | Feedback
The clear emerging threat to NeuroOne Medical Technologies is the rise of **High-Intensity Focused Ultrasound (HIFU)** as a non-invasive therapeutic option for neurological disorders.
NeuroOne's business includes the development of electrode-based ablation solutions for conditions like essential tremors and Parkinson's disease. HIFU offers a non-invasive method for precisely ablating target brain tissue without requiring incisions or implanted electrodes, which directly competes with and could potentially displace NeuroOne's invasive ablation technology in the future. HIFU is already approved and gaining traction for the treatment of essential tremor and tremor-dominant Parkinson's disease, and its applications are expanding, presenting a significant and evolving challenge to companies relying on invasive surgical ablation methods.
AI Analysis | Feedback
NeuroOne Medical Technologies Corporation (NMTC) operates in several significant addressable markets related to neurological devices and therapies. The estimated market sizes for their main products and services are as follows:
- Electroencephalography (EEG) Devices Market (including cEEG and sEEG recording): The global electroencephalography devices market was estimated at USD 1.52 billion in 2025 and is predicted to increase to approximately USD 3.65 billion by 2034, expanding at a CAGR of 10.24%. Separately, the global epilepsy monitoring devices market, which encompasses EEG and intracranial EEG (including sEEG), is estimated at USD 621.62 million in 2026 and is projected to reach USD 797.85 million by 2031. Within this, intracranial EEG shows a projected CAGR of 9.01% during 2026-2031. The global SEEG Depth Electrodes market was approximately USD 300 million in 2023 and is projected to grow to USD 530 million by 2032. Additionally, the global subdural electrodes market was valued at USD 48.84 million in 2025 and is projected to grow to USD 105.43 million by 2034.
- Spinal Cord Stimulation Devices: The global spinal cord stimulator market size was valued at USD 3,437.62 million in 2024 and is projected to increase to USD 7,243.98 million by 2032, growing at a CAGR of 9.83%. North America is identified as the largest market.
- Deep Brain Stimulation (DBS) Devices: The global deep brain stimulation devices market size is valued at USD 1.61 billion in 2025 and is predicted to increase to approximately USD 4.26 billion by 2035, expanding at a CAGR of 10.22%. This market is driven by the rising prevalence of neurological conditions such as Parkinson's disease, dystonia, and essential tremor.
- Radiofrequency (RF) Ablation Devices: The global radiofrequency ablation devices market size was estimated at USD 3.93 billion in 2021 and is projected to reach USD 12.08 billion by 2031, with a CAGR of 12.2%. NeuroOne Medical Technologies has commenced a limited commercial launch of its OneRF ablation system. Another estimate for the global radiofrequency ablation devices market indicates a size of USD 3,934.08 million in 2024, expected to reach USD 9,125.13 million by 2032.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for NeuroOne Medical Technologies (NMTC) over the next 2-3 years:
- Continued Commercial Adoption and Expansion of the OneRF Brain Ablation System: NeuroOne anticipates sustained growth through the increasing adoption of its OneRF brain ablation system. Management has noted continued clinical uptake and sequential sales increases for this product. The company is also establishing a registry to collect patient outcomes, which is expected to further bolster adoption.
- Launch and Market Penetration of the OneRF Trigeminal Nerve Ablation System: The company has received FDA 510(k) clearance for its OneRF Trigeminal Nerve Ablation System, with initial patient treatments showing successful pain relief. NeuroOne projects completing the limited launch of this system by the end of the second fiscal quarter of 2026, indicating a new product entering the facial pain market.
- Advancement and Commercialization of the Drug Delivery Program: NeuroOne is accelerating its drug delivery program, with devices for commercial use and investigational clinical studies anticipated to be available in the third fiscal quarter of 2026, which is approximately six months ahead of original projections. This represents an expansion into a new product and service category.
- Strategic Partnerships and Licensing Agreements: The company is actively pursuing diligence discussions with strategic partners for potential licensing and collaborations across several technologies, including its trigeminal nerve ablation and lower back pain programs. Previous license revenue from an expanded distribution agreement with Zimmer Biomet demonstrates the potential for this type of revenue generation.
- International Expansion Initiatives: NeuroOne is working towards obtaining ISO 13485 certification, which is a crucial step for commercializing its products internationally. This will open new markets for the company's thin film electrode technology.
AI Analysis | Feedback
Share Issuance
- In March 2026, NeuroOne Medical Technologies Corporation conducted a private placement, issuing 1,000,000 common shares for gross proceeds of $670,400.
- In April 2025, the company completed an oversubscribed capital raise with institutional investors, generating $8.3 million in net proceeds.
- During the second quarter of fiscal year 2025 (ended March 31, 2025), NeuroOne sold common stock under an At-The-Market (ATM) Program, receiving net proceeds of $0.3 million, before eliminating the program in April 2025.
Inbound Investments
- In April 2025, NeuroOne successfully completed an $8.3 million capital raise with institutional investors, providing funding for operations through at least the end of fiscal year 2026.
- The company has an exclusive distribution agreement with Zimmer Biomet, which generated $3.0 million in license revenue in Q1 Fiscal 2025 (ended December 31, 2024). This expanded partnership also includes a significant upfront payment.
Capital Expenditures
- NeuroOne Medical Technologies Corp reported $41,000 in capital expenditures in Q2 2026.
- Net cash used in investing activities was $24,416 in Q2 2026.
- The company anticipates substantial increases in expenses to develop and commercialize its electrode technology, conduct trials, seek regulatory approvals, and manufacture and distribute products.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| NeuroOne Medical Technologies Earnings Notes | 12/16/2025 | |
| With NeuroOne Medical Technologies Stock Surging, Have You Considered The Downside? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to NMTC.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03312026 | PGNY | Progyny | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 03272026 | CNC | Centene | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -0.6% |
| 03272026 | OSCR | Oscar Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.0% | 3.0% | -2.6% |
| 03202026 | WAT | Waters | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -0.4% | -0.4% | -3.3% |
| 03202026 | GILD | Gilead Sciences | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.6% | 1.6% | -2.2% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 91.50 |
| Mkt Cap | 120.9 |
| Rev LTM | 30,300 |
| Op Inc LTM | 5,835 |
| FCF LTM | 4,846 |
| FCF 3Y Avg | 4,452 |
| CFO LTM | 6,164 |
| CFO 3Y Avg | 5,674 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 9.0% |
| Rev Chg 3Y Avg | 7.9% |
| Rev Chg Q | 8.9% |
| QoQ Delta Rev Chg LTM | 2.2% |
| Op Inc Chg LTM | 14.5% |
| Op Inc Chg 3Y Avg | 5.3% |
| Op Mgn LTM | 19.2% |
| Op Mgn 3Y Avg | 18.4% |
| QoQ Delta Op Mgn LTM | 0.5% |
| CFO/Rev LTM | 21.1% |
| CFO/Rev 3Y Avg | 20.1% |
| FCF/Rev LTM | 16.8% |
| FCF/Rev 3Y Avg | 15.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 120.9 |
| P/S | 4.7 |
| P/Op Inc | 21.5 |
| P/EBIT | 18.2 |
| P/E | 24.9 |
| P/CFO | 19.3 |
| Total Yield | 4.9% |
| Dividend Yield | 1.6% |
| FCF Yield 3Y Avg | 3.0% |
| D/E | 0.1 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -4.8% |
| 3M Rtn | -15.1% |
| 6M Rtn | -16.2% |
| 12M Rtn | -12.3% |
| 3Y Rtn | 15.0% |
| 1M Excs Rtn | -13.2% |
| 3M Excs Rtn | -19.3% |
| 6M Excs Rtn | -23.1% |
| 12M Excs Rtn | -42.9% |
| 3Y Excs Rtn | -54.4% |
Price Behavior
| Market Price | $4.84 | |
| Market Cap ($ Bil) | 0.2 | |
| First Trading Date | 03/16/2018 | |
| Distance from 52W High | -87.3% | |
| 50 Days | 200 Days | |
| DMA Price | $25.82 | $28.12 |
| DMA Trend | up | down |
| Distance from DMA | -81.3% | -82.8% |
| 3M | 1YR | |
| Volatility | 188.3% | 112.7% |
| Downside Capture | 4.04 | 1.97 |
| Upside Capture | -162.22 | 110.48 |
| Correlation (SPY) | -3.3% | 10.1% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -2.44 | -0.48 | 0.05 | 1.00 | 1.12 | 0.82 |
| Up Beta | -4.84 | 2.28 | -0.10 | 1.06 | -0.06 | -0.02 |
| Down Beta | -1.72 | 0.12 | -0.49 | 0.99 | 2.55 | 2.01 |
| Up Capture | -250% | -176% | 48% | 75% | 132% | 21% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 10 | 20 | 31 | 60 | 124 | 348 |
| Down Capture | -279% | -51% | 15% | 113% | 130% | 99% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 12 | 21 | 31 | 64 | 124 | 380 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NMTC | |
|---|---|---|---|---|
| NMTC | -75.2% | 112.1% | -0.19 | - |
| Sector ETF (XLV) | 9.6% | 16.0% | 0.39 | 7.5% |
| Equity (SPY) | 21.1% | 12.9% | 1.32 | 13.4% |
| Gold (GLD) | 50.9% | 27.5% | 1.49 | 7.8% |
| Commodities (DBC) | 25.2% | 16.2% | 1.40 | 1.7% |
| Real Estate (VNQ) | 17.5% | 13.7% | 0.93 | 5.5% |
| Bitcoin (BTCUSD) | -7.8% | 42.6% | -0.08 | 9.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NMTC | |
|---|---|---|---|---|
| NMTC | -55.0% | 111.2% | -0.09 | - |
| Sector ETF (XLV) | 6.4% | 14.6% | 0.25 | 10.0% |
| Equity (SPY) | 10.8% | 17.1% | 0.49 | 11.7% |
| Gold (GLD) | 22.6% | 17.8% | 1.04 | 6.0% |
| Commodities (DBC) | 11.6% | 18.8% | 0.51 | 5.3% |
| Real Estate (VNQ) | 4.4% | 18.8% | 0.14 | 10.0% |
| Bitcoin (BTCUSD) | 5.2% | 56.5% | 0.31 | 6.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NMTC | |
|---|---|---|---|---|
| NMTC | -34.1% | 109.7% | -0.06 | - |
| Sector ETF (XLV) | 9.8% | 16.5% | 0.48 | 8.6% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 10.6% |
| Gold (GLD) | 14.3% | 15.9% | 0.75 | 6.4% |
| Commodities (DBC) | 8.5% | 17.6% | 0.40 | 5.2% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.24 | 7.8% |
| Bitcoin (BTCUSD) | 68.4% | 66.9% | 1.07 | 6.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 12/17/2025 | -5.5% | 1.3% | 27.7% |
| 8/14/2025 | -3.5% | -12.6% | 3.4% |
| 5/13/2025 | 3.4% | 6.1% | -9.3% |
| 12/17/2024 | 4.5% | -1.9% | 38.8% |
| 8/14/2024 | -1.5% | 4.9% | 12.0% |
| 5/14/2024 | -7.0% | -8.8% | -16.5% |
| 12/14/2023 | -11.0% | -19.2% | -20.3% |
| 8/14/2023 | -3.8% | -5.6% | -8.3% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 5 | 4 | 8 |
| # Negative | 9 | 10 | 6 |
| Median Positive | 1.3% | 5.5% | 9.7% |
| Median Negative | -3.8% | -7.8% | -15.8% |
| Max Positive | 4.5% | 46.6% | 70.8% |
| Max Negative | -25.4% | -34.9% | -25.3% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/17/2026 | 10-Q |
| 09/30/2025 | 12/17/2025 | 10-K |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 02/12/2025 | 10-Q |
| 09/30/2024 | 12/17/2024 | 10-K |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 02/13/2024 | 10-Q |
| 09/30/2023 | 12/15/2023 | 10-K |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/12/2023 | 10-Q |
| 12/31/2022 | 02/13/2023 | 10-Q |
| 09/30/2022 | 12/22/2022 | 10-K |
| 06/30/2022 | 08/11/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q1 2026 Earnings Reported 2/17/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 10.50 Mil | 15.4% | Higher New | Actual: 9.10 Mil for 2025 | |||
| 2026 Revenue Growth | 17.0% | ||||||
Prior: Q4 2025 Earnings Reported 12/17/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Funding Runway | |||||||
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Christianson, Mark | Business Development Director | Direct | Sell | 9092025 | 0.74 | 30,000 | 22,203 | 171,139 | Form |
| 2 | Christianson, Mark | Business Development Director | Direct | Sell | 6052025 | 0.58 | 10,000 | 5,804 | 151,769 | Form |
| 3 | Christianson, Mark | Business Development Director | Direct | Sell | 5232025 | 0.65 | 14 | 9 | 182,298 | Form |
| 4 | Christianson, Mark | Business Development Director | Direct | Sell | 5232025 | 0.62 | 8,967 | 5,586 | 169,139 | Form |
| 5 | Christianson, Mark | Business Development Director | Direct | Sell | 5212025 | 0.67 | 8,006 | 5,330 | 188,716 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.